Incannex Healthcare (NASDAQ:IXHL – Get Free Report) and Aditxt (NASDAQ:ADTX – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations and institutional ownership.
Risk & Volatility
Incannex Healthcare has a beta of 7, suggesting that its share price is 600% more volatile than the S&P 500. Comparatively, Aditxt has a beta of 1.37, suggesting that its share price is 37% more volatile than the S&P 500.
Insider and Institutional Ownership
0.4% of Incannex Healthcare shares are owned by institutional investors. Comparatively, 15.5% of Aditxt shares are owned by institutional investors. 9.1% of Incannex Healthcare shares are owned by company insiders. Comparatively, 0.0% of Aditxt shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Profitability
This table compares Incannex Healthcare and Aditxt’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Incannex Healthcare | N/A | -25.62% | -24.46% |
| Aditxt | -360,152.50% | -374.60% | -105.93% |
Valuation and Earnings
This table compares Incannex Healthcare and Aditxt”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Incannex Healthcare | $90,000.00 | 280.28 | -$19.30 million | ($1.69) | -1.19 |
| Aditxt | $14,336.00 | 0.02 | -$41.71 million | ($100,788.35) | -0.00 |
Incannex Healthcare has higher revenue and earnings than Aditxt. Incannex Healthcare is trading at a lower price-to-earnings ratio than Aditxt, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a breakdown of recent recommendations and price targets for Incannex Healthcare and Aditxt, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Incannex Healthcare | 2 | 0 | 1 | 0 | 1.67 |
| Aditxt | 1 | 0 | 0 | 0 | 1.00 |
Incannex Healthcare currently has a consensus target price of $18.00, suggesting a potential upside of 795.52%. Given Incannex Healthcare’s stronger consensus rating and higher possible upside, equities research analysts clearly believe Incannex Healthcare is more favorable than Aditxt.
Summary
Incannex Healthcare beats Aditxt on 12 of the 14 factors compared between the two stocks.
About Incannex Healthcare
Incannex Healthcare Limited (NASDAQ: IXHL) is an Australia-based clinical-stage pharmaceutical company developing cannabinoid- and psychedelic-assisted therapies for conditions with significant unmet medical needs. The company’s research programs are focused on areas including sleep disorders, pain, inflammation, mental health and traumatic brain injury. Incannex’s lead programs have included IHL-42X, an investigational combination therapy being developed for obstructive sleep apnea, and IHL-675A, a cannabinoid-based therapy studied for inflammatory conditions.
About Aditxt
Aditxt, Inc. (NASDAQ: ADTX) is a biotechnology company focused on developing technologies designed to monitor and improve the human immune system. Its work centers on immune profiling, precision health and personalized medicine, with the goal of helping healthcare providers and researchers better understand individual immune responses. The company’s primary technology platform, AditxtScore, is designed to analyze multiple immune system biomarkers simultaneously. The platform is intended for applications including disease detection, monitoring immune responses to infections and vaccines, and supporting the development of personalized treatment strategies.
Receive News & Ratings for Incannex Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incannex Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
